Shenzhen - Delayed Quote CNY

Jafron Biomedical Co.,Ltd. (300529.SZ)

26.15 +2.85 (+12.23%)
At close: April 26 at 3:04 PM GMT+8
Key Events
Loading Chart for 300529.SZ
DELL
  • Previous Close 23.30
  • Open 22.40
  • Bid 26.14 x --
  • Ask 26.15 x --
  • Day's Range 24.06 - 26.47
  • 52 Week Range 15.88 - 29.67
  • Volume 32,811,619
  • Avg. Volume 6,770,378
  • Market Cap (intraday) 21.118B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 47.55
  • EPS (TTM) 0.55
  • Earnings Date --
  • Forward Dividend & Yield 0.67 (2.56%)
  • Ex-Dividend Date May 31, 2023
  • 1y Target Est 26.62

Jafron Biomedical Co.,Ltd. engages in the research, development, production, and sales of blood purification products for hemadsorption industry in China and internationally. The company offers solutions for ESRD diseases, acute poisoning, critical illness, hepatopathy, immunological disorders, kidney, and liver diseases; HA series hemoperfusion cartridge, BS bilirubin adsorption column and DNA immunoadsorption column, hemoperfusion machine, and blood purification machine; and other products, such as hemodialyzer, hemodialysis concentrate, disinfectants, resin bandages, online hemodialysis powder bag/bucket, and adsorbable suture with needles. The company was founded in 1989 and is based in Zhuhai, China.

www.jafroninternational.com

--

Full Time Employees

December 31

Fiscal Year Ends

Related News

Performance Overview: 300529.SZ

Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

300529.SZ
17.63%
SSE Composite Index
3.82%

1-Year Return

300529.SZ
7.53%
SSE Composite Index
5.40%

3-Year Return

300529.SZ
70.12%
SSE Composite Index
11.10%

5-Year Return

300529.SZ
11.32%
SSE Composite Index
1.13%

Compare To: 300529.SZ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 300529.SZ

Valuation Measures

Annual
As of 4/26/2024
  • Market Cap

    21.12B

  • Enterprise Value

    20.15B

  • Trailing P/E

    47.55

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    10.69

  • Price/Book (mrq)

    6.79

  • Enterprise Value/Revenue

    10.33

  • Enterprise Value/EBITDA

    35.91

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    25.06%

  • Return on Assets (ttm)

    6.82%

  • Return on Equity (ttm)

    14.65%

  • Revenue (ttm)

    2.09B

  • Net Income Avi to Common (ttm)

    524.73M

  • Diluted EPS (ttm)

    0.55

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.14B

  • Total Debt/Equity (mrq)

    55.79%

  • Levered Free Cash Flow (ttm)

    735.4M

Research Analysis: 300529.SZ

Analyst Price Targets

25.23 Low
26.62 Average
26.15 Current
28.00 High
 

Fair Value

 

Company Insights: 300529.SZ

People Also Watch